Vanda Pharmaceuticals (VNDA) Raw Materials (2014 - 2015)
Vanda Pharmaceuticals recorded quarterly Raw Materials of $128000.0 in Q3 2015, little changed quarter-over-quarter from $128000.0 in Q2 2015, and down 39.91% year-over-year from $213000.0 in Q3 2014.
Vanda Pharmaceuticals' Raw Materials history runs 2 years deep, the most recent figure standing at $128000.0 for Q3 2015.
- In Q3 2015, Raw Materials fell 39.91% year-over-year to $128000.0; the TTM figure through Sep 2015 stood at $128000.0 (down 39.91% YoY), while the FY2014 annual figure was $198000.0, changed N/A from the prior year.
- Raw Materials came in at $128000.0 for Q3 2015 at Vanda Pharmaceuticals, roughly flat from $128000.0 in the prior quarter.
- In the past five years, Raw Materials ranged from a high of $213000.0 in Q3 2014 to a low of $128000.0 in Q2 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | 128,000.00 |
| Jun 30, 2015 | 128,000.00 |
| Mar 31, 2015 | 162,000.00 |
| Dec 31, 2014 | 198,000.00 |
| Sep 30, 2014 | 213,000.00 |
| Jun 30, 2014 | 145,000.00 |
| Mar 31, 2014 | 143,000.00 |